You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.
By combining genome sequence data with phylogenetics and other clues, two teams looked at the SARS-CoV-2 introductions that sparked outbreaks in North America and Europe.
The test is based on 13 genes that form a gene signature in the blood of children with Kawasaki disease, and it enables KD to be distinguished from other diseases.
The San Diego-based firm anticipates launching an LDT for early-stage lung cancer out of a CLIA-certified, CAP-accredited lab within the next two years.
With single-cell transcriptomic, T cell receptor, and B cell receptor data, researchers tracked immune shifts in tissue and peripheral blood samples from ulcerative colitis patients.
The sequence-based analysis suggests oncogene-containing circular, extrachromosomal sequences occur in most cancer types and may correspond with poorer patient outcomes.
The University of California, San Diego spinout is developing a technology that uses microbial DNA signatures for the early detection of cancer.
TargetCancer is activating two enrollment sites and setting up a remote consenting process so patients with rare cancers can be seen at local community hospitals.
Zeesan's test may be used by any CLIA-certified high-complexity lab, while UCSD's test, which uses pooled samples, must be performed by the university.
In PNAS this week: possible cancer targets due to homologous recombination defects, approach for detecting digenic disease inheritance, and more.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.